XLO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.59%

Insider Buying (Last 12 Months): $72,976.52

Insider Selling (Last 12 Months): $8,581.86

Xilio Therapeutics Insider Trading History Chart

Xilio Therapeutics Share Price & Price History

^$0.74

▲ +0.035 (4.96%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Xilio Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/17/2025	James Samuel Shannon	Director	Buy	25,000	$0.69	$17,250.00	70,000
6/16/2025	James Samuel Shannon	Director	Buy	45,000	$0.69	$31,050.00	45,000
6/16/2025	Rene Russo	CEO	Buy	36,289	$0.68	$24,676.52	281,172
1/2/2025	Christopher James Frankenfield	CFO	Sell	6,954	$0.98	$6,814.92	12,421
1/2/2025	Kevin M Brennan	SVP	Sell	1,803	$0.98	$1,766.94	3,197
4/2/2024	Gilead Sciences, Inc.	Major Shareholder	Buy	485,250	$0.76	$368,790.00	7,345,473
2/8/2024	Venture Fund Xi L.P. Atlas	Major Shareholder	Sell	733	$0.64	$469.12	2,019,563
1/11/2024	Venture Fund Xi L.P. Atlas	Major Shareholder	Sell	1,566	$0.87	$1,362.42	2,021,836

SEC Filings (Institutional Ownership Changes) for Xilio Therapeutics (NASDAQ:XLO)

54.29% of Xilio Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Xilio Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/14/2025	Squarepoint Ops LLC	328,794	$0.28M	0.0%	+39.6%	0.634%
8/15/2025	Bridgeway Capital Management LLC	56,081	$38K	0.0%	-21.1%	0.108%
5/16/2025	ADAR1 Capital Management LLC	40,000	$29K	0.0%	N/A	0.077%
4/29/2025	Avantax Planning Partners Inc.	150,399	$0.11M	0.0%	N/A	0.290%
2/17/2025	Trustees of Columbia University in the City of New York	249,635	$0.24M	0.0%	N/A	0.568%
2/17/2025	Balyasny Asset Management L.P.	343,230	$0.33M	0.0%	+26.0%	0.781%
2/17/2025	Aptus Capital Advisors LLC	41,000	$39K	0.0%	N/A	0.093%
2/14/2025	Gilead Sciences Inc.	9,105,451	$8.70M	0.6%	N/A	20.713%
2/13/2025	Raymond James Financial Inc.	50,086	$48K	0.0%	N/A	0.114%
2/13/2025	Renaissance Technologies LLC	296,617	$0.28M	0.0%	+11.4%	0.675%
2/12/2025	Geode Capital Management LLC	358,422	$0.34M	0.0%	+6.0%	0.815%
2/12/2025	Takeda Pharmaceutical Co. Ltd.	1,475,121	$1.42M	5.3%	N/A	3.356%
2/6/2025	Raymond James Financial Inc.	50,086	$48K	0.0%	N/A	0.114%
11/16/2024	Geode Capital Management LLC	338,192	$0.27M	0.0%	+85.0%	0.769%
8/12/2024	XTX Topco Ltd	33,289	$32K	0.0%	N/A	0.076%
8/9/2024	Renaissance Technologies LLC	295,000	$0.28M	0.0%	+18.3%	0.799%
5/6/2024	Atlas Venture Life Science Advisors LLC	992,912	$1.07M	0.1%	-64.0%	2.690%
4/22/2024	PFG Investments LLC	30,000	$32K	0.0%	N/A	0.087%
2/15/2024	Octagon Capital Advisors LP	1,785,000	$0.98M	0.2%	-23.0%	6.481%
11/14/2022	Ergoteles LLC	12,941	$38K	0.0%	-26.3%	0.047%
8/15/2022	Laurion Capital Management LP	142,900	$0.42M	0.0%	N/A	0.520%
7/27/2022	Bailard Inc.	36,632	$0.11M	0.0%	N/A	0.133%
5/16/2022	Deerfield Management Company L.P. Series C	2,078,692	$14.70M	0.3%	-3.5%	7.567%
5/12/2022	Monashee Investment Management LLC	163,066	$1.15M	0.3%	-23.9%	0.594%
2/15/2022	Davidson Kempner Capital Management LP	29,000	$0.46M	0.0%	N/A	0.109%
2/14/2022	Deerfield Management Company L.P. Series C	2,154,061	$33.74M	0.7%	N/A	8.078%
2/14/2022	Ghisallo Capital Management LLC	30,000	$0.48M	0.0%	N/A	0.113%
2/14/2022	Soleus Capital Management L.P.	477,495	$7.64M	0.8%	N/A	1.791%
2/11/2022	Granite Point Capital Management L.P.	10,000	$0.16M	0.0%	N/A	0.038%
2/9/2022	AJU IB Investment Co. Ltd.	667,742	$10.68M	14.9%	N/A	2.504%
2/8/2022	Northern Trust Corp	63,034	$1.01M	0.0%	N/A	0.236%
2/7/2022	Monashee Investment Management LLC	214,253	$3.43M	0.8%	N/A	0.803%
2/7/2022	RiverVest Venture Management LLC	1,441,444	$23.06M	16.5%	N/A	5.406%
2/2/2022	New York State Common Retirement Fund	5,568	$89K	0.0%	N/A	0.021%

Data available starting January 2016

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $0.74

$0.70

$0.75

50 Day Range

MA: $0.78

$0.70

$0.86

52 Week Range

Now: $0.74

$0.62

$1.70

Volume

734,996 shs

Average Volume

627,315 shs

Market Capitalization

$38.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Xilio Therapeutics?: Xilio Therapeutics' top insider shareholders include:
Gilead Sciences, Inc (Major Shareholder)
Venture Fund Xi LP Atlas (Major Shareholder)
Rene Russo (CEO)
James Samuel Shannon (Director)
Christopher James Frankenfield (CFO)
Kevin M Brennan (SVP)
Learn More about top insider investors at Xilio Therapeutics.
Who are the major institutional investors of Xilio Therapeutics?: Xilio Therapeutics' top institutional investors include:
Squarepoint Ops LLC — 0.63%
Learn More about top institutional investors of Xilio Therapeutics stock.
Which major investors are buying Xilio Therapeutics stock?: In the previous quarter, XLO stock was acquired by institutional investors including:
Squarepoint Ops LLC
In the previous year, these company insiders have bought Xilio Therapeutics stock:
Gilead Sciences, Inc (Major Shareholder)
Venture Fund Xi LP Atlas (Major Shareholder)
Rene Russo (CEO)
Learn More investors buying Xilio Therapeutics stock.